FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037899894> ?p ?o ?g. }

• W2037899894 endingPage "1589" @default.
• W2037899894 startingPage "1581" @default.
• W2037899894 abstract "Although antibiotics are a common treatment for acne, the difficulties inherent to effective antimicrobial penetration in sebum and selective antimicrobial action in the skin are compounded by increasing resistance of Propionibacterium acnes clinical isolates. To address these problems, we engineered Pentobra, a peptide–aminoglycoside molecule that has multiple mechanisms of antibacterial action and investigated whether it can be a potential candidate for the treatment of acne. Pentobra combines the potent ribosomal activity of aminoglycosides with the bacteria-selective membrane-permeabilizing abilities of antimicrobial peptides. Pentobra demonstrated potent and selective killing of P. acnes but not against human skin cells in vitro. In direct comparison, Pentobra demonstrated bactericidal activity and drastically outperformed free tobramycin (by 5–7 logs) against multiple P. acnes clinical strains. Moreover, electron microscopic studies showed that Pentobra had robust membrane activity, as treatment with Pentobra killed P. acnes cells and caused leakage of intracellular contents. Pentobra may also have potential anti-inflammatory effects as demonstrated by suppression of some P. acnes–induced chemokines. Importantly, the killing activity was maintained in sebaceous environments as Pentobra was bactericidal against clinical isolates in comedones extracts isolated from human donors. Our work demonstrates that equipping aminoglycosides with selective membrane activity is a viable approach for developing antibiotics against P. acnes that are effective in cutaneous environments. Although antibiotics are a common treatment for acne, the difficulties inherent to effective antimicrobial penetration in sebum and selective antimicrobial action in the skin are compounded by increasing resistance of Propionibacterium acnes clinical isolates. To address these problems, we engineered Pentobra, a peptide–aminoglycoside molecule that has multiple mechanisms of antibacterial action and investigated whether it can be a potential candidate for the treatment of acne. Pentobra combines the potent ribosomal activity of aminoglycosides with the bacteria-selective membrane-permeabilizing abilities of antimicrobial peptides. Pentobra demonstrated potent and selective killing of P. acnes but not against human skin cells in vitro. In direct comparison, Pentobra demonstrated bactericidal activity and drastically outperformed free tobramycin (by 5–7 logs) against multiple P. acnes clinical strains. Moreover, electron microscopic studies showed that Pentobra had robust membrane activity, as treatment with Pentobra killed P. acnes cells and caused leakage of intracellular contents. Pentobra may also have potential anti-inflammatory effects as demonstrated by suppression of some P. acnes–induced chemokines. Importantly, the killing activity was maintained in sebaceous environments as Pentobra was bactericidal against clinical isolates in comedones extracts isolated from human donors. Our work demonstrates that equipping aminoglycosides with selective membrane activity is a viable approach for developing antibiotics against P. acnes that are effective in cutaneous environments. antimicrobial peptide colony-forming unit" @default.
• W2037899894 created "2016-06-24" @default.
• W2037899894 creator A5004655713 @default.
• W2037899894 creator A5033656130 @default.
• W2037899894 creator A5044600186 @default.
• W2037899894 creator A5047389385 @default.
• W2037899894 creator A5047439189 @default.
• W2037899894 creator A5063469501 @default.
• W2037899894 creator A5069450479 @default.
• W2037899894 creator A5073102114 @default.
• W2037899894 creator A5078191755 @default.
• W2037899894 creator A5084449412 @default.
• W2037899894 date "2015-06-01" @default.
• W2037899894 modified "2023-10-12" @default.
• W2037899894 title "Pentobra: A Potent Antibiotic with Multiple Layers of Selective Antimicrobial Mechanisms against Propionibacterium Acnes" @default.
• W2037899894 cites W1493113567 @default.
• W2037899894 cites W1495270894 @default.
• W2037899894 cites W1571292455 @default.
• W2037899894 cites W1584683177 @default.
• W2037899894 cites W1598136901 @default.
• W2037899894 cites W1673257055 @default.
• W2037899894 cites W1901312711 @default.
• W2037899894 cites W1965252702 @default.
• W2037899894 cites W1965614061 @default.
• W2037899894 cites W1968291031 @default.
• W2037899894 cites W1973056259 @default.
• W2037899894 cites W1974619687 @default.
• W2037899894 cites W1982551127 @default.
• W2037899894 cites W1987349623 @default.
• W2037899894 cites W1989761771 @default.
• W2037899894 cites W1989998611 @default.
• W2037899894 cites W1997152791 @default.
• W2037899894 cites W2004682883 @default.
• W2037899894 cites W2005445428 @default.
• W2037899894 cites W2007296377 @default.
• W2037899894 cites W2013160328 @default.
• W2037899894 cites W2014069105 @default.
• W2037899894 cites W2014287269 @default.
• W2037899894 cites W2014716916 @default.
• W2037899894 cites W2015156802 @default.
• W2037899894 cites W2017032430 @default.
• W2037899894 cites W2017191377 @default.
• W2037899894 cites W2019585324 @default.
• W2037899894 cites W2020015356 @default.
• W2037899894 cites W2025777803 @default.
• W2037899894 cites W2050871371 @default.
• W2037899894 cites W2054602599 @default.
• W2037899894 cites W2058223359 @default.
• W2037899894 cites W2063116767 @default.
• W2037899894 cites W2074097589 @default.
• W2037899894 cites W2076515212 @default.
• W2037899894 cites W2090042814 @default.
• W2037899894 cites W2093649670 @default.
• W2037899894 cites W2094741750 @default.
• W2037899894 cites W2107679123 @default.
• W2037899894 cites W2108174511 @default.
• W2037899894 cites W2132134286 @default.
• W2037899894 cites W2132874962 @default.
• W2037899894 cites W2154611836 @default.
• W2037899894 cites W2158852280 @default.
• W2037899894 cites W2159239386 @default.
• W2037899894 cites W2164128280 @default.
• W2037899894 cites W2168502185 @default.
• W2037899894 cites W2171863770 @default.
• W2037899894 cites W2335415688 @default.
• W2037899894 cites W4211104405 @default.
• W2037899894 cites W4236997449 @default.
• W2037899894 cites W4250024072 @default.
• W2037899894 doi "https://doi.org/10.1038/jid.2015.40" @default.
• W2037899894 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4430421" @default.
• W2037899894 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25668237" @default.
• W2037899894 hasPublicationYear "2015" @default.
• W2037899894 type Work @default.
• W2037899894 sameAs 2037899894 @default.
• W2037899894 citedByCount "16" @default.
• W2037899894 countsByYear W20378998942016 @default.
• W2037899894 countsByYear W20378998942017 @default.
• W2037899894 countsByYear W20378998942018 @default.
• W2037899894 countsByYear W20378998942019 @default.
• W2037899894 countsByYear W20378998942020 @default.
• W2037899894 countsByYear W20378998942021 @default.
• W2037899894 countsByYear W20378998942022 @default.
• W2037899894 countsByYear W20378998942023 @default.
• W2037899894 crossrefType "journal-article" @default.
• W2037899894 hasAuthorship W2037899894A5004655713 @default.
• W2037899894 hasAuthorship W2037899894A5033656130 @default.
• W2037899894 hasAuthorship W2037899894A5044600186 @default.
• W2037899894 hasAuthorship W2037899894A5047389385 @default.
• W2037899894 hasAuthorship W2037899894A5047439189 @default.
• W2037899894 hasAuthorship W2037899894A5063469501 @default.
• W2037899894 hasAuthorship W2037899894A5069450479 @default.
• W2037899894 hasAuthorship W2037899894A5073102114 @default.
• W2037899894 hasAuthorship W2037899894A5078191755 @default.
• W2037899894 hasAuthorship W2037899894A5084449412 @default.
• W2037899894 hasBestOaLocation W20378998941 @default.
• W2037899894 hasConcept C185592680 @default.
• W2037899894 hasConcept C2775832221 @default.
• W2037899894 hasConcept C2777458120 @default.

• next